Pfizer Inc., Groton, U.S.
Drug Metab Pharmacokinet. 2011 Jun;26(3):266-79. doi: 10.2133/dmpk.DMPK-10-RG-109. Epub 2011 Mar 4.
The metabolism of 3,4-dihydro-7-[4-(1-naphthalenyl)-1-piperazinyl]butoxy]-1,8-naphthyridin-2(1H)-one (NPBN) was investigated in rats. Animals were administered 30 mg/kg NPBN that was labeled with both tritium and carbon-14. The mass recovery of drug-related material was 96-98%, with almost all material excreted in feces. Metabolism occurred by oxidation reactions followed by conjugation. The main route of metabolism of NPBN occurred via oxidation of the naphthylene ring, which led to naphthol and dihydrodiol metabolites as well as a relatively novel N-dearylated metabolite in which the naphthylene ring was removed. In vitro investigation in rat liver microsomes also showed a glutathione adduct on the naphthalene and a glutathione adduct of naphthoquinone, which, along with the dihydrodiol metabolite, is consistent with the initial generation of an epoxide. A mechanism is proposed whereby the N-dearylation arises via epoxidation, followed by formation of an exocyclic iminium ion intermediate that is hydrolyzed to yield the N-dearylated metabolite. An additional mechanism involves oxidation of the naphthol metabolite via a radical mechanism, since this metabolite was also shown to undergo N-dearylation.
对 3,4-二氢-7-[4-(1-萘基)-1-哌嗪基]丁氧基]-1,8-萘啶-2(1H)-酮(NPBN)在大鼠体内的代谢进行了研究。动物被给予标记有氚和碳-14 的 30mg/kg NPBN。药物相关物质的质量回收率为 96-98%,几乎所有物质都从粪便中排出。代谢通过氧化反应和结合反应进行。NPBN 的主要代谢途径是通过萘环的氧化,导致萘酚和二氢二醇代谢物以及一种相对新颖的 N-去芳基代谢物,其中萘环被去除。在大鼠肝微粒体中的体外研究也表明萘上有谷胱甘肽加合物和萘醌的谷胱甘肽加合物,这与环氧的初始生成一致。提出了一种机制,其中 N-去芳基化是通过环氧化,然后形成一个非环亚氨基离子中间体,然后水解生成 N-去芳基代谢物。另一种机制涉及萘酚代谢物通过自由基机制的氧化,因为该代谢物也被证明会发生 N-去芳基化。